Bringing doctors together

or

A free, private network for verified physicians

Leading voices

Dr. Isaac Yang

Brain & Spinal Tumor · UCLA

View

Dr. Rohan Ramakrishna

Brain & Spinal Tumor · WCM

View

Dr. Philip Schauer

Bariatric Surgery · PBRC

View

Dr. Justin Hovey, FAAP, FACP, DABOM

Obesity Medicine · Noland Hospital Dothan II

View

Dr. Kimberly Gudzune

Obesity Medicine · JHU

View

Dr. Richard Dutton

General Anesthesiology · UMSOM

View

Dr. Sarah Ro

Obesity Medicine · UNC Health Care

View

Dr. Rebecca Andrews

Primary Care · UCHC

View

Dr. Jed Wolpaw

General Anesthesiology · Johns Hopkins

View

Dr. Matt Sherrer

Perioperative Med · UAB

View
  • Discover your community

  • Stay current

  • A profile that represents you

  • Find your people

About RoonPrivacyTerms

    Overview

    [68Ga]-DOTATATE PET Standardized Uptake Value Reduction after Bevacizumab in High-grade Meningioma: A Potential Treatment Response Biomarker.

    Sep 2, 2026DOI: 10.3174/ajnr.a9260Journal ArticleAJNR

    Written by: Kellen Vo VuHannah G OtisAndrew BrandmaierJoseph R OsbornePhilip E StiegRohan R RamakrishnaArsalan HaghdelSean H KimBenjamin LiechtyKate RosenKathryn BealSusan C PannulloJonathan P S KniselyRajiv S MaggeMary WelchFabio IwamotoPeter C PanJana Ivanidze

    Find these authors on Roon

    RR

    Dr. Rohan Ramakrishna

    Brain & Spinal Tumor · WCM

    KR

    Dr. Kate Rosen

    Brain & Spinal Tumor · WCM

    Summary

    Bevacizumab, a monoclonal antibody targeting vascular endothelial growth factor A, is emerging as a promising therapy for high-grade meningioma, an aggressive central nervous system tumor with limited systemic treatment options. While clinical stabilization has been observed in prior trials, radiographic response on conventional MRI is often minimal, highlighting the need for alternative imaging biomarkers to monitor treatment effect. [68Ga]-DOTATATE is a somatostatin analog that binds with high affinity to somatostatin receptor 2, which is overexpressed in meningiomas. In this case series, we present 3 patients with World Health Organization grade 3 meningioma who underwent baseline and follow-up [68Ga]-DOTATATE PET imaging in the setting of bevacizumab therapy. All patients had biopsy-confirmed high-grade disease and demonstrated multifocal [68Ga]-DOTATATE-avid lesions at baseline. Across 12 lesions, 67% showed a reduction in maximum standardized uptake value (SUVmax) after therapy. In contrast, matched control patients who underwent serial [68Ga]-DOTATATE PET imaging without bevacizumab or other systemic therapy demonstrated no significant change in SUVmax. Linear mixed-effects modeling confirmed a significant treatment effect, with a 7.2-unit greater reduction in SUVmax in the bevacizumab-treated group than in controls (P = .01). Our findings raise the possibility that [68Ga]-DOTATATE PET may capture early biologic responses to antiangiogenic therapy not reflected by anatomic imaging alone, potentially reflecting changes in somatostatin receptor expression, tumor perfusion, or metabolic activity. This series suggests that [68Ga]-DOTATATE PET may serve as a noninvasive, biologically informative adjunct to conventional imaging and supports further investigation of its role as a molecular imaging biomarker of bevacizumab response in high-grade meningioma.
    KRDr. Kate Rosen

    Dr. Kate Rosen

    Neurosurgery · Brain & Spinal Tumor
    Weill Cornell Medicine
    katerosen